TickerFacts.

Arcus Biosciences, Inc. (RCUS): Cash & Equivalents

Annual figures by period end, from SEC filings.

$222.00M
As of 2025-12-31
$150.00M
As of 2026-06-30
+2.5%
3-year compound annual growth
+5.1%
5-year compound annual growth
2016-12-31: $65.16M2017-12-31: $98.43M2018-12-31: $71.06M2019-12-31: $57.94M2020-12-31: $173.41M2021-12-31: $148.00M2022-12-31: $206.00M2023-12-31: $127.00M2024-12-31: $150.00M2025-12-31: $222.00M$222.00M
2016-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$222.00M+48.0%2026-02-25, Balance as of period end
2024-12-31$150.00M+18.1%2026-02-25, Balance as of period end
2023-12-31$127.00M-38.3%2025-02-25, Balance as of period end
2022-12-31$206.00M+39.2%2024-02-21, Balance as of period end
2021-12-31$148.00M-14.7%2023-02-28, Balance as of period end
2020-12-31$173.41M+199.3%2022-02-23, Balance as of period end
2019-12-31$57.94M-18.5%2021-02-25, Balance as of period end
2018-12-31$71.06M-27.8%2020-03-05, Balance as of period end
2017-12-31$98.43M+51.1%2019-03-05, Balance as of period end
2016-12-31$65.16Mn/a2019-03-05, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Arcus Biosciences, Inc. (RCUS)2025-12-31$222.00M+48.0%
Keros Therapeutics, Inc. (KROS)2025-12-31$287.42M-48.7%
Schrodinger, Inc. (SDGR)2025-12-31$230.52M+56.5%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$184.84M+256.4%
Anaptysbio, Inc (ANAB)2025-12-31$238.20M+93.5%
Arvinas, Inc. (ARVN)2025-12-31$142.90M+42.2%
Puma Biotechnology, Inc. (PBYI)2025-12-31$29.64M-57.2%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$174.93M+141.9%
Harrow, Inc. (HROW)2025-12-31$72.93M+54.4%

Compare RCUS, KROS, SDGR, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗